Val Warner, PA
Medical · Layton, UTNPI 1366819575
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Alnylam Pharmaceuticals Inc. at 34.9% of the total. Among medical clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 907 payments — averaging $55.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alnylam Pharmaceuticals Inc.$18K
- Pfizer$12K
- Biohaven Pharmaceuticals, Inc.$8K
- AbbVie$4K
- Biohaven Pharmaceutical Holding Company Ltd.$1K
- Novo Nordisk$876
- plus $7K from 54 others
What the payments were for
- Consulting fees$4,2658%
- Speaking & faculty fees$24,97549%
- Travel & lodging$7,56115%
- Food & beverage$13,71027%
- Education$320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GIVLAARI$16,107
- NURTEC ODT$14,211
- ZAVZPRET$5,115
How this compares
$50,543 in reported general payments places this provider in the 95th percentile of 263 medical providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 94 | $103,605 |
| MounjaroTirzepatide | 54 | $71,277 |
| EliquisApixaban | 63 | $43,823 |
| CreonLipase/Protease/Amylase | 12 | $42,554 |
| VraylarCariprazine Hcl | 18 | $37,251 |
| Nurtec OdtRimegepant Sulfate | 17 | $29,583 |
| JardianceEmpagliflozin | 24 | $25,605 |
| MyrbetriqMirabegron | 27 | $22,028 |
| XareltoRivaroxaban | 28 | $20,606 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $19,646 |
| LinzessLinaclotide | 19 | $16,321 |
| FarxigaDapagliflozin Propanediol | 15 | $12,346 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $12,226 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 233 | $6,875 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $5,928 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $876 | $103,60594 claims |
| AbbVieCreon, Vraylar, Linzess, Synthroid | $4,114 | $97,28471 claims |
| PfizerEliquis, Nurtec Odt | $11,782 | $73,40780 claims |
| Lilly USA, LLCMounjaro | $599 | $71,27754 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $190 | $35,21456 claims |
| Boehringer IngelheimJardiance | $225 | $25,60524 claims |
| Astellas Pharma US IncMyrbetriq | $390 | $22,02827 claims |
| Johnson & JohnsonXarelto | $91 | $20,60628 claims |
| MerckJanumet | $12 | $5,92811 claims |
| Redhill Biopharma Inc.Movantik | $14 | $5,77012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 263 medical providers in Utah.
Other medical in Layton
- Steinia LewisLayton$3K
- Mont RobinsLayton$3K
- Elisa WilcoxSalt Lake City$178K
- Viet leSalt Lake City$42K
- Carmelo DiazSalt Lake City$35K
- Shari CombeSalt Lake City$22K
- Kelly MikesellOgden$19K
- Jennifer CoombsSlc$12K
- Brandon HansenRiverton$10K
- Daniel CorryCedar City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.